A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
| 対象疾患 | Dermatitis, Atopic |
|---|---|
| 相 | 第2相 |
| スポンサー | GlaxoSmithKline |
| ステータス | 早期終了 |
| 参加者数 | 161 名 |
| 介入（薬剤） | GSK1070806 |
| 開始日 | 2023年11月16日 |
| 完了日 | 2025年7月23日 |
| 結果公開日 | 2026年6月3日 |
概要
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16
| Placebo | -44.53 ± 40.805 Percent Change |
|---|---|
| GSK1070806 Dose Level 1 | -42.86 ± 36.186 Percent Change |
| GSK1070806 Dose Level 2 | -69.95 ± 33.363 Percent Change |
| GSK1070806 Dose Level 3 | -41.49 ± 43.341 Percent Change |
| GSK1070806 Dose Level 4 | -58.08 ± 33.129 Percent Change |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen